Clinical Review Report: adalimumab (Humira) [Internet]

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2016 Apr.


The objective of this report is to perform a systematic review of the beneficial and harmful effects of adalimumab via subcutaneous injection at recommended doses for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy or who are intolerant to such therapies.

[Table: see text]

Publication types

  • Review

Grant support

Funding: CADTH receives funding from Canada’s federal, provincial, and territorial governments, with the exception of Quebec.